We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

JEOL

JEOL is a leading global supplier of electron microscopes, ion beam instruments, mass spectrometers and NMR spectrome... read more Featured Products: More products

Download Mobile App





JEOL Ltd. Introduces BioMajesty Series of Clinical Chemistry Analyzers at MEDICA 2019

By LabMedica International staff writers
Posted on 18 Nov 2019
JEOL Ltd. More...
(Tokyo, Japan) introduced its BioMajesty series of clinical chemistry analyzers featuring unique but proven technologies at this year's MEDICA, the world's largest annual medical technology trade fair, which took place from 18-21 November in Düsseldorf, Germany. At the 2019 edition of MEDICA, more than 5,000 exhibitors from 70 countries presented their newest products and ideas. The event also drew more than 120,000 trade visitors from over 170 countries.

JEOL offers the BioMajesty series of clinical chemistry analyzers which use micro volume of samples and reagents to deliver highly-accurate, high-speed processing through the incorporation of a sample dilution tray, which is an outstanding unique feature of all BioMajesty analyzers.

At the 2019 edition of MEDICA, JEOL showcased its BioMajesty series of clinical chemistry analyzers, which include the JCA-ZS050, JCA-BM6070/C and JCA-BM6010/C. The JCA-ZS050 clinical chemistry analyzer is bolstered by the breakthrough technology and unique dilution mechanism of the series. The JCA-ZS050 boasts of extra-micro-volume measurement with minimum 40μL reaction volume. The 1,800 throughput/hour next-generation chemistry analyzer from JEOL brings innovative operation and simple maintenance, while assuring high-precision data empowered by its novel wash mechanism.

The JCA-BM6070/C clinical chemistry analyzer has 2,400 tests/hour throughput, achieving unprecedented ultrafast processing capability in the 2.0-second cycle time. While realizing minimum reaction volume of 60μl by its unique pre-dilution mechanism, it offers high data reliability and excellent cost benefits.

The JCA-BM6010/C is a compact, reliable chemistry system with versatile functions, offering a maximum throughput of 800 tests/hour for photometry and 1,200 tests/hour with ISE. Bolstered by unique micro-volume technology, a strong tradition of BioMajesty series, it streamlines the daily laboratory routine by automatic on-board hemolysis for HbA1c. The JCA-BM6010/C’s0 superior usability with STAT port and Smart Pause/Smart Start features in its optimized space-saving design help deliver more flexibility.

Related Links:
JEOL Ltd.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Automated Urinalysis Solution
UN-9000
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image Credit: 123RF

Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer

Inherited cancer risk can affect children, adolescents and young adults, but it may not always be apparent from tumor type or family history alone. Some cancer syndromes require specialized expertise and... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.